Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01086358 · ClinicalTrials.gov registry record · Phase 4
Does Treximet Improve Productivity and Patient Satisfaction Due to Sustained Response and Consistency of Response?
A Phase 4 study of Workplace Migraine Treatment, sponsored by The Cleveland Clinic.
- Completed
- Registry status
- Phase 4
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT01086358 is a Phase 4 study of Workplace Migraine Treatment that has completed, run by The Cleveland Clinic. The registered enrollment target is 60 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01086358, a Phase 4 study of Workplace Migraine Treatment, has completed, sponsored by The Cleveland Clinic.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
Researchers want to learn about work productivity after treatment of a migraine headache with your usual migraine medication as compared to your work productivity after treatment with Treximet. During this research subjects will take Treximet to treat 3 workday migraine attacks. For a second part of the research subjects will take their usual prescribed medication for 3 workday migraine attacks. The subjects will complete questionnaires after treating each migraine.
Conditions Studied
Interventions
- DRUG Triptan
- DRUG Treximet 85Mg-500Mg Tablet
Study Locations (1)
Ohio
- Cleveland Clinic, 9500 Euclid Avenue, C-21 - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2009-09 |
| Est. Completion | 2016-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01086358
The ClinicalTrials.gov registry entry for NCT01086358 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Cleveland Clinic, which has 688 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Workplace Migraine Treatment appearing as the primary indexed condition, and to 2 interventions - of which Triptan is the first listed.
NCT01086358 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT01086358 about?
NCT01086358 is a clinical study titled "Does Treximet Improve Productivity and Patient Satisfaction Due to Sustained Response and Consistency of Response?". Researchers want to learn about work productivity after treatment of a migraine headache with your usual migraine medication as compared to your work productivity after treatment with Treximet. During this research subjects will take Treximet to treat 3 workday migraine attacks. For a second part o...
What is the current status of trial NCT01086358?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 60 participants. The study started on 2009-09. Estimated completion is 2016-08.
What conditions does trial NCT01086358 study?
This clinical trial studies the following conditions: Workplace Migraine Treatment.
What interventions are being tested in trial NCT01086358?
The interventions under investigation include: Triptan (DRUG), Treximet 85Mg-500Mg Tablet (DRUG).
Who is sponsoring clinical trial NCT01086358?
This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01086358 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.